OR WAIT null SECS
January 17, 2024
Charles River’s off-the-shelf rep/cap plasmids are intended to simplify gene therapy supply chains.
The acquisition marks a pivotal expansion for the company into the US market.
January 11, 2024
Pluri has launched PluriCDMO, a new contract development and manufacturing organization business that will offer cell therapy manufacturing services.
January 10, 2024
Cherwell Laboratories’ cleanroom microbiology solutions will join AnalytiChem’s group of seven companies across Europe, North America, and Australia.
January 09, 2024
The expansion will boost solid-phase peptide synthesis total reactor volume to 32,000 L.
December 28, 2023
Is increasing molecular diversity pushing manufacturing ecosystem consolidation toward turnkey solutions?
Tome Bioscience is facilitating the transition in biology from the editing phase to the cut-and-paste phase.
December 27, 2023
Andelyn Biosciences has been selected by Ultragenyx to manufacture UX111, that company’s gene therapy for treating Sanfilippo Syndrome.
December 20, 2023
Following the divestiture of its Elusys subsidiary and other non-core assets, NightHawk Biosciences will transform into a pure-play large-molecule CDMO.
December 14, 2023
RoslinCT will manufacture Vertex Pharmaceuticals’ CRISPR-based gene therapy, Casgevy, recently approved for treating sickle cell disease and β thalassemia.